Please assess the completion status of the following clinical trial:

Trial Title: Somatuline Autogel: Acromegaly Self/Partner Injection Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The patient must have a clinical diagnosis of acromegaly~* The patient must have been tested and shown to have a GH level less than or equal to 10 micrograms/L within 28 days prior to the baseline visit~* The patient must be currently treated with Somatuline Autogel and have been stable on their current dose for at least 6 months immediately prior to screening~* The patient must be able to store study medication in a refrigerator in their own home~Exclusion Criteria:~* The patient has had pituitary surgery (adenomectomy) within 6 months prior to screening~* The patient has received pituitary radiotherapy within one year prior to screening~* The patient is likely to require pituitary surgery (adenomectomy) or to receive radiotherapy during the study period~* The patient is currently receiving a GH antagonist or a somatostatin analogue other than Somatuline Autogel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).